Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

New genotypes and molecular characterization of Enterocytozoon bieneusi in pet birds in Southwestern China.

Deng L, Yue CJ, Chai YJ, Wang WY, Su XY, Zhou ZY, Wang LQ, Li LY, Liu HF, Zhong ZJ, Cao SZ, Hu YC, Fu HL, Peng GN.

Int J Parasitol Parasites Wildl. 2019 Aug 9;10:164-169. doi: 10.1016/j.ijppaw.2019.08.001. eCollection 2019 Dec.

2.

First report of Blastocystis in giant pandas, red pandas, and various bird species in Sichuan province, southwestern China.

Deng L, Yao JX, Liu HF, Zhou ZY, Chai YJ, Wang WY, Zhong ZJ, Deng JL, Ren ZH, Fu HL, Yan X, Yue CJ, Peng GN.

Int J Parasitol Parasites Wildl. 2019 Jun 26;9:298-304. doi: 10.1016/j.ijppaw.2019.06.007. eCollection 2019 Aug.

3.

How Medic-Patient Communication and Relationship Influence Chinese Patients' Treatment Adherence.

Zhong ZJ, Nie J, Xie X, Liu K.

J Health Commun. 2019;24(1):29-37. doi: 10.1080/10810730.2018.1561768. Epub 2018 Dec 30.

PMID:
30596351
4.

Elizabethkingia miricola infection in Chinese spiny frog (Quasipaa spinosa).

Lei XP, Yi G, Wang KY, OuYang P, Chen F, Huang XL, Huang C, Lai WM, Zhong ZJ, Huo CL, Yang ZX.

Transbound Emerg Dis. 2019 Mar;66(2):1049-1053. doi: 10.1111/tbed.13101. Epub 2018 Dec 31.

PMID:
30554477
5.

FV3-like ranavirus infection outbreak in black-spotted pond frogs (Rana nigromaculata) in China.

Mu WH, Geng Y, Yu ZH, Wang KY, Huang XL, Ou YP, Chen DF, He CL, Zhong ZJ, Yang ZX, Lai WM.

Microb Pathog. 2018 Oct;123:111-114. doi: 10.1016/j.micpath.2018.06.047. Epub 2018 Jul 2.

PMID:
29986839
6.

[Analysis and evaluation of chemically induced artificial agarwood].

Zhou X, Chen LY, Chen XD, Zhong ZJ, Li HH, Zhang WM, Gao XX.

Zhongguo Zhong Yao Za Zhi. 2017 Aug;42(16):3159-3166. doi: 10.19540/j.cnki.cjcmm.20170512.004. Chinese.

PMID:
29171236
7.

Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular Atrophy.

Finkel RS, Mercuri E, Darras BT, Connolly AM, Kuntz NL, Kirschner J, Chiriboga CA, Saito K, Servais L, Tizzano E, Topaloglu H, Tulinius M, Montes J, Glanzman AM, Bishop K, Zhong ZJ, Gheuens S, Bennett CF, Schneider E, Farwell W, De Vivo DC; ENDEAR Study Group.

N Engl J Med. 2017 Nov 2;377(18):1723-1732. doi: 10.1056/NEJMoa1702752.

8.

Genetic variation in mitochondrial cox2 of Heterakis gallinarum from poultry in Sichuan, China.

Gu XB, Wang BJ, Zhao XB, Li YF, Yang GY, Lai WM, Zhong ZJ, Peng GN.

Mitochondrial DNA A DNA Mapp Seq Anal. 2018 May;29(4):629-634. doi: 10.1080/24701394.2017.1334771. Epub 2017 Jun 8.

PMID:
28595493
9.

Dihydromyricetin induces apoptosis and cytoprotective autophagy through ROS-NF-κB signalling in human melanoma cells.

Zhou DZ, Sun HY, Yue JQ, Peng Y, Chen YM, Zhong ZJ.

Free Radic Res. 2017 May;51(5):517-528. doi: 10.1080/10715762.2017.1328552.

PMID:
28482716
10.

Epidemiology of Cryptosporidium infection in cattle in China: a review.

Gong C, Cao XF, Deng L, Li W, Huang XM, Lan JC, Xiao QC, Zhong ZJ, Feng F, Zhang Y, Wang WB, Guo P, Wu KJ, Peng GN.

Parasite. 2017;24:1. doi: 10.1051/parasite/2017001. Epub 2017 Jan 18. Review.

11.

Mitochondrial genomes of Heterakis gallinae and Heterakis beramporia support that they belong to the infraorder Ascaridomorpha.

Wang BJ, Gu XB, Yang GY, Wang T, Lai WM, Zhong ZJ, Liu GH.

Infect Genet Evol. 2016 Jun;40:228-235. doi: 10.1016/j.meegid.2016.03.012. Epub 2016 Mar 12.

PMID:
26980606
12.
13.

Absence of population genetic structure in Heterakis gallinarum of chicken from Sichuan, inferred from mitochondrial cytochrome c oxidase subunit I gene.

Gu X, Zhu JY, Jian KL, Wang BJ, Peng XR, Yang GY, Wang T, Zhong ZJ, Peng KY.

Mitochondrial DNA A DNA Mapp Seq Anal. 2016 Sep;27(5):3612-7. doi: 10.3109/19401736.2015.1079825. Epub 2015 Sep 22.

PMID:
26394200
14.

Paclitaxel-induced lung injury and its amelioration by parecoxib sodium.

Liu WJ, Zhong ZJ, Cao LH, Li HT, Zhang TH, Lin WQ.

Sci Rep. 2015 Aug 10;5:12977. doi: 10.1038/srep12977.

15.

Benefits of fluorine-18 fludeoxyglucose positron emission tomography in secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer.

Peng P, Zhu ZH, Zhong ZJ, Zheng K, Yang JX, Cao DY, Shen K.

Br J Radiol. 2015 Aug;88(1052):20150109. doi: 10.1259/bjr.20150109. Epub 2015 May 20.

16.

Sequence analysis of origins of replication in the Saccharomyces cerevisiae genomes.

Li WC, Zhong ZJ, Zhu PP, Deng EZ, Ding H, Chen W, Lin H.

Front Microbiol. 2014 Nov 18;5:574. doi: 10.3389/fmicb.2014.00574. eCollection 2014.

17.

Predicting the subcellular localization of mycobacterial proteins by incorporating the optimal tripeptides into the general form of pseudo amino acid composition.

Zhu PP, Li WC, Zhong ZJ, Deng EZ, Ding H, Chen W, Lin H.

Mol Biosyst. 2015 Feb;11(2):558-63. doi: 10.1039/c4mb00645c. Epub 2014 Dec 1.

PMID:
25437899
18.

Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials.

Furie R, Petri MA, Strand V, Gladman DD, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups.

Lupus Sci Med. 2014 Jun 26;1(1):e000031. doi: 10.1136/lupus-2014-000031. eCollection 2014.

19.

Relevance of different results of different anti-double-stranded DNA assays in reporting clinical studies: comment on the article by Petri et al. Reply.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW.

Arthritis Rheumatol. 2014 Feb;66(2):480. doi: 10.1002/art.38251. No abstract available.

20.

Synthesis and broad-spectrum antiviral activity of some novel benzo-heterocyclic amine compounds.

Zhang DJ, Sun WF, Zhong ZJ, Gao RM, Yi H, Li YH, Peng ZG, Li ZR.

Molecules. 2014 Jan 15;19(1):925-39. doi: 10.3390/molecules19010925.

21.

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.

Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA; LBSL02/99 Study Group.

J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368. Epub 2013 Nov 1.

22.

Bioavailability, Pharmacokinetics, and Safety of Belimumab Administered Subcutaneously in Healthy Subjects.

Cai WW, Fiscella M, Chen C, Zhong ZJ, Freimuth WW, Subich DC.

Clin Pharmacol Drug Dev. 2013 Oct;2(4):349-57. doi: 10.1002/cpdd.54. Epub 2013 Aug 26.

PMID:
27121939
23.

Synthesis and antiviral activity of a novel class of (5-oxazolyl)phenyl amines.

Zhong ZJ, Zhang DJ, Peng ZG, Li YH, Shan GZ, Zuo LM, Wu LT, Li SY, Gao RM, Li ZR.

Eur J Med Chem. 2013 Nov;69:32-43. doi: 10.1016/j.ejmech.2013.07.053. Epub 2013 Aug 15.

PMID:
23999140
24.

Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials.

Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, Zhong ZJ, Freimuth WW; BLISS-52 and BLISS-76 Study Groups.

Arthritis Rheum. 2013 Aug;65(8):2143-53. doi: 10.1002/art.37995.

25.

Efficacy and safety of belimumab in patients with rheumatoid arthritis: a phase II, randomized, double-blind, placebo-controlled, dose-ranging Study.

Stohl W, Merrill JT, McKay JD, Lisse JR, Zhong ZJ, Freimuth WW, Genovese MC.

J Rheumatol. 2013 May;40(5):579-89. doi: 10.3899/jrheum.120886. Epub 2013 Apr 1.

PMID:
23547209
26.

Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.

Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, Zhong ZJ, Clarke AE; BLISS-52 and -76 Study Groups.

Ann Rheum Dis. 2014 May;73(5):838-44. doi: 10.1136/annrheumdis-2012-202865. Epub 2013 Mar 22.

27.

Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.

Dooley MA, Houssiau F, Aranow C, D'Cruz DP, Askanase A, Roth DA, Zhong ZJ, Cooper S, Freimuth WW, Ginzler EM; BLISS-52 and -76 Study Groups.

Lupus. 2013 Jan;22(1):63-72. doi: 10.1177/0961203312465781.

PMID:
23263865
28.

Safety profile of belimumab: pooled data from placebo-controlled phase 2 and 3 studies in patients with systemic lupus erythematosus.

Wallace DJ, Navarra S, Petri MA, Gallacher A, Thomas M, Furie R, Levy RA, van Vollenhoven RF, Cooper S, Zhong ZJ, Freimuth W, Cervera R; BLISS-52 and -76, and LBSL02 Study Groups.

Lupus. 2013 Feb;22(2):144-54. doi: 10.1177/0961203312469259. Epub 2012 Dec 4.

PMID:
23213069
29.

Evaluation of the CEL-100 videolaryngoscope(TM) for double-lumen tracheal tube insertion after failure using the Macintosh laryngoscope.

Lin WQ, Quan SB, Liu WJ, Zhang TH, Li HT, Zhong ZJ, Cao LH.

Anaesthesia. 2012 Nov;67(11):1232-6. doi: 10.1111/j.1365-2044.2012.07261.x. Epub 2012 Jul 24.

30.

[Promoter methylation of DAPK1, RAR-β and MGMT in exfoliated cervical cytology and its clinical application].

Zhong ZJ, Yang JX, Cao DY, Sun Y, Sun LL, Cheng XM, Chen J, Lang JH, Shen K.

Zhonghua Fu Chan Ke Za Zhi. 2012 Mar;47(3):196-200. Chinese.

PMID:
22781071
31.

Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.

Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, McCune WJ, Tegzová D, McKay JD, Avila-Armengol HE, Utset TO, Zhong ZJ, Hough DR, Freimuth WW, Migone TS; BLISS-76 Study Group.

J Rheumatol. 2012 Aug;39(8):1632-40. Epub 2012 Jun 15.

32.

Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.

Merrill JT, Ginzler EM, Wallace DJ, McKay JD, Lisse JR, Aranow C, Wellborne FR, Burnette M, Condemi J, Zhong ZJ, Pineda L, Klein J, Freimuth WW; LBSL02/99 Study Group.

Arthritis Rheum. 2012 Oct;64(10):3364-73. doi: 10.1002/art.34564.

33.

Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials.

Manzi S, Sánchez-Guerrero J, Merrill JT, Furie R, Gladman D, Navarra SV, Ginzler EM, D'Cruz DP, Doria A, Cooper S, Zhong ZJ, Hough D, Freimuth W, Petri MA; BLISS-52 and BLISS-76 Study Groups.

Ann Rheum Dis. 2012 Nov;71(11):1833-8. doi: 10.1136/annrheumdis-2011-200831. Epub 2012 May 1.

34.

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

van Vollenhoven RF, Petri MA, Cervera R, Roth DA, Ji BN, Kleoudis CS, Zhong ZJ, Freimuth W.

Ann Rheum Dis. 2012 Aug;71(8):1343-9. doi: 10.1136/annrheumdis-2011-200937. Epub 2012 Feb 15.

35.

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.

Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW; BLISS-52 Study Group; BLISS-76 Study Group.

Arthritis Rheum. 2012 Jul;64(7):2328-37. doi: 10.1002/art.34400.

36.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group.

Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613.

37.

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.

Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA; BLISS-52 Study Group.

Lancet. 2011 Feb 26;377(9767):721-31. doi: 10.1016/S0140-6736(10)61354-2. Epub 2011 Feb 4.

PMID:
21296403
38.

DFT and MP2 investigations of L-proline and its hydrated complexes.

Li XJ, Zhong ZJ, Wu HZ.

J Mol Model. 2011 Oct;17(10):2623-30. doi: 10.1007/s00894-011-0957-z. Epub 2011 Jan 25.

PMID:
21264484
39.

Synthesis and antiviral activities of synthetic glutarimide derivatives.

Ji XY, Zhong ZJ, Xue ST, Meng S, He WY, Gao RM, Li YH, Li ZR.

Chem Pharm Bull (Tokyo). 2010 Nov;58(11):1436-41.

40.

[Comparison of sevoflurane and propofol in combined anesthesia induction with remifentanil for tracheal intubation with fiberoptic bronchoscope].

Tan HY, Cao LH, Huang W, Zhong ZJ, Lin WQ, Zeng WA.

Nan Fang Yi Ke Da Xue Xue Bao. 2010 Aug;30(8):1857-9. Chinese.

PMID:
20813685
41.

Sharp and asymmetric transmission response in metal-dielectric-metal plasmonic waveguides containing Kerr nonlinear media.

Zhong ZJ, Xu Y, Lan S, Dai QF, Wu LJ.

Opt Express. 2010 Jan 4;18(1):79-86. doi: 10.1364/OE.18.000079.

PMID:
20173825
42.

Novel evidence-based systemic lupus erythematosus responder index.

Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1143-51. doi: 10.1002/art.24698.

43.

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699.

44.

[Postoperative analgesia with fentanyl combined with flurbiprofen axetil following gynecologic surgery for turnor].

Lin WQ, Cao LH, Zhong ZJ, Wen LL, Bai XH.

Nan Fang Yi Ke Da Xue Xue Bao. 2009 Feb;29(2):313-5. Chinese.

PMID:
19246310
45.

[Effects of the lung protective ventilatory strategy on proinflammatory cytokine release during one-lung ventilation].

Lin WQ, Lu XY, Cao LH, Wen LL, Bai XH, Zhong ZJ.

Ai Zheng. 2008 Aug;27(8):870-3. Chinese.

PMID:
18710624
46.

[One case of congenital lissencephaly].

Xu YL, Yin H, Qin JB, Zhong ZJ.

Zhonghua Er Ke Za Zhi. 2003 Nov;41(11):803. Chinese. No abstract available.

PMID:
14728881
47.

Photoinduced magnetization in a two-dimensional cobalt octacyanotungstate.

Arimoto Y, Ohkoshi S, Zhong ZJ, Seino H, Mizobe Y, Hashimoto K.

J Am Chem Soc. 2003 Aug 6;125(31):9240-1.

PMID:
12889922
48.
49.

Crystal structure and magnetic properties of an octacyanometalate-based three-dimensional tungstate(V)-manganese(II) bimetallic assembly.

Zhong ZJ, Seino H, Mizobe Y, Hidai M, Verdaguer M, Ohkoshi S, Hashimoto K.

Inorg Chem. 2000 Oct 30;39(22):5095-101.

PMID:
11233207
50.

Quantitative high-performance liquid chromatography analysis of DNA oxidized in vitro and in vivo.

Frenkel K, Zhong ZJ, Wei HC, Karkoszka J, Patel U, Rashid K, Georgescu M, Solomon JJ.

Anal Biochem. 1991 Jul;196(1):126-36.

PMID:
1888026

Supplemental Content

Loading ...
Support Center